Skip to main content

No Increased Risk of Neurologic Complications With Transradial PCI


STOKE-ON-TRENT, United Kingdom — Performing PCI via the radial artery does not increase the risk of neurological complications when compared with conventional transfemoral PCI, a new European analysis shows [1]. Researchers say the results are reassuring, given that more and more operators are beginning to switch over to the transradial approach for various procedures.
"This analysis of almost 350 000 PCI procedures has not found any increase in the risk of neurologic complications associated with transradial access via either the right (the predominant radial artery used) or left radial artery," writeDr Karim Ratib (University Hospital of North Staffordshire, Stoke-on-Trent, UK) and colleagues in their study, published online December 26, 2012 in the American Heart Journal. "The results are reassuring, as the data were collected over a transitional period in UK access-site practice, during which transradial access increased from 17.1% to 50.8% of all PCI cases."
To heart wire , Dr Sunil Rao (Duke University Medical Center, Durham, NC), who was not involved in the study but who is a proponent of transradial PCI, was also reassured by the data.
"There is concern by femoral operators that radial increases stroke risk because of catheter exchanges in the ascending aorta, and there is a belief among radial operators that it reduces stroke risk because of the routine anticoagulation given even for diagnostic cases," said Rao. "This study and others like theSCIPION trial reported in the American Heart Journal shows that the stroke risk is probably the same for radial and femoral, with the attendant benefits of radial on vascular complications."
The current study is a retrospective analysis of the British Cardiovascular Intervention Societydatabase between 2006 and 2010. During this time, there were 124 616 procedures performed via the radial artery and 223 476 procedures performed via the femoral artery. Patients treated with the transradial approach were younger, had less diabetes, and were more likely to have prior cerebrovascular disease and peripheral vascular disease. Patients treated with transfemoral access were more likely to have a history of previous CABG surgery and renal impairment.
Overall, there were 247 neurologic complications in patients treated via the femoral artery (0.11%) and 139 neurologic complications in the transradial group (0.11%). In a multivariate-adjusted risk model, transradial PCI was not associated with an increased risk of complications compared with conventional PCI. The strongest predictors of neurologic complications were the use of an intra-aortic balloon pump, prior cerebrovascular events, pre-PCI shock, and PCI for acute coronary syndrome (ACS).
The researchers did observe an increase in rate of neurologic complications over time, increasing from 0.08% to 0.14% during the five-year period. This increase, they explain, might be related to the shift in patients undergoing PCI, such as more ACS patients undergoing the procedure. The increase in neurologic complications, such as cerebral bleeding events, might be associated with the more intensive antithrombotic regime in this population.
"For other interventional communities that are also undergoing rapid evolution in access-site practice, our data suggest that there is no neurologic hazard associated with rapid adoption of transradial access," conclude Ratib et al.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more